Open access
Open access
Powered by Google Translator Translator

[Not published yet] Full-dose Heparin best for moderate COVID-19 regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials

1 Feb, 2021 | 01:58h | UTC

Full-Dose Heparin Best for Moderate COVID-19 Regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials – MedPage Today (free registration required)

Trial results: ATTACC, ACTIV-4a & REMAP-CAP multiplatform RCT Results of interim analysis – ATTACC Trial

News release: Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients – National Institutes of Health

 


Stay Updated in Your Specialty

No spam, just news.